Viatris Inc.

Valuation Analysis

About the Company

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients b

Viatris Inc. Stock at a Glance

Viatris Inc. (VTRS) is currently trading at $16.48 with a market capitalization of $19.2B. The 52-week range spans from $8.63 to $17.53; the current price is 6% below the yearly high. Year-over-year revenue growth stands at +8.1%.

💰 Dividend

Viatris Inc. pays an annual dividend of $0.48 per share, representing a yield of 2.91%. The payout ratio stands at 960%. The elevated payout ratio reflects a mature dividend policy.

📊 Analyst Rating

8 analysts rate Viatris Inc. (VTRS) on consensus: Buy. The average price target is $17.81, implying +8.09% from the current price. Analyst price targets range from $12.00 to $23.00.

Viatris Inc.: The Investment Case in Detail

Viatris Inc. (VTRS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valuation in Context

With a PEG ratio of 0.15, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.61x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Viatris Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.